You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug EXCEDRIN EXTRA STRENGTH HEADACHE


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for EXCEDRIN EXTRA STRENGTH HEADACHE

Last updated: February 25, 2026

What is the role of excipients in EXCEDRIN EXTRA STRENGTH HEADACHE?

Excipients in EXCEDRIN EXTRA STRENGTH HEADACHE (acetaminophen, aspirin, and caffeine) serve multiple purposes:

  • Fillers and bulking agents: Provide volume necessary for tablet formation, ensuring consistent dosage.
  • Binders: Enhance tablet integrity during compression.
  • Disintegrants: Facilitate rapid disintegration for quick release.
  • Lubricants: Reduce friction for ease of manufacturing.
  • Colorants and flavoring agents: Improve consumer acceptance.
  • Stabilizers: Preserve active ingredient potency over shelf life.

The formulation typically includes excipients like microcrystalline cellulose, sodium starch glycolate, lactose, magnesium stearate, and colorants, tailored for rapid release and bioavailability.

How does excipient choice impact product performance?

Selecting excipients influences pharmacokinetics, shelf stability, manufacturing efficiency, and patient experience. For EXCEDRIN, rapid disintegration and absorption align with consumer expectations for headache relief. Optimizing excipients enhances:

  • Bioavailability: Facilitates fast onset.
  • Stability: Prevents degradation of active compounds.
  • Manufacturing: Ensures consistent quality and scalability.
  • Sensory attributes: Affects taste, mouthfeel, and swallowability.

What are the current market trends and innovation opportunities?

Trends in excipient development:

  • Film-coating technology: Improves coating uniformity, taste masking, and controlled release.
  • Superdisintegrants: Accelerate disintegration, beneficial for payloads requiring rapid onset.
  • High-potency excipients: Enable dose reduction, lower excipient load, and minimize pill size.
  • Natural excipients: Meet consumer demand for clean label products.

Innovation opportunities:

  • Use of multifunctional excipients: Combine disintegrant, binder, and stabilizer functions to simplify formulations.
  • Enhanced stability excipients: Protect against moisture and oxidation, extending shelf life.
  • Sustained or controlled release platforms: Offer differentiated products such as extended relief formulations.
  • Personalized delivery systems: Incorporate pH-sensitive or enzyme-responsive excipients for site-specific release.

What are the commercial implications of excipient selection?

Choosing excipients affects manufacturing costs, regulatory compliance, and market positioning:

  • Manufacturing costs: Natural or novel excipients may carry higher costs but can justify premium pricing.
  • Regulatory pathways: Use of Generally Recognized as Safe (GRAS) excipients streamlines approval.
  • Brand differentiation: Proprietary formulations with unique excipient profiles can create competitive advantages.
  • Patient acceptance: Improved taste and swallowability increase adherence and brand loyalty.

How do patent strategies relate to excipient use?

Patent protection often targets formulations, including excipient combinations:

  • Formulation patents: Cover unique excipient compositions for rapid disintegration or modified release.
  • Method patents: Protect manufacturing processes employing specific excipients.
  • Implication: Innovation related to excipients can extend lifecycle and provide market exclusivity.

Summary of key excipient considerations:

Aspect Detail
Focus Rapid disintegration, stability, bioavailability
Trends Natural, multifunctional, controlled-release excipients
Opportunities Novel excipients, formulation simplification, personalized delivery
Market Impact Cost efficiency, regulatory compliance, differentiation

Key Market Opportunities

  • Developing formulations with natural excipients to meet "clean label" demands.
  • Incorporating sustained-release excipients for extended relief products.
  • Customizing excipient profiles for delivery via novel routes like dissolvable strips or liquids.
  • Building patent portfolios around innovative excipient combinations and manufacturing processes.
  • Collaborating with excipient suppliers to customize formulations for specific market segments.

Key Takeaways

  • Excipient selection is central to product performance, manufacturing efficiency, and market differentiation for EXCEDRIN EXTRA STRENGTH HEADACHE.
  • Emerging trends include natural, multifunctional, and controlled-release excipients.
  • Innovation in excipient technology can create opportunities for patent protection and premium pricing.
  • Strategic excipient choice influences regulatory pathways and consumer acceptance.
  • Focused development on excipient profiles aligns with trends toward personalized, convenient, and "clean label" formulations.

FAQs

1. How do excipients impact the onset of action for headache medicines?
Excipients like superdisintegrants and rapid-soluble fillers facilitate quick tablet breakdown, leading to faster absorption of active ingredients and quicker relief.

2. Are natural excipients suitable for high-dose formulations like EXCEDRIN?
Yes, but they may require careful selection to ensure stability, solubility, and efficacy at higher loadings, often necessitating formulation adjustments.

3. Can proprietary excipient blends provide a competitive advantage?
Yes, unique blends can improve performance, reduce pill size, or extend shelf life, supporting patent strategies and branding.

4. What regulatory issues influence excipient selection?
Use of excipients with GRAS status simplifies approval; novel excipients may require extensive safety assessments and regulatory filings.

5. How does excipient innovation support product differentiation?
Innovative excipients enable controlled release, taste masking, and reduced pill size, improving user experience and market appeal.


References

[1] McGinity, J. W., & Williams, L. A. (2014). Manufacture of controlled-release dosage forms. CRC Press.

[2] Bansal, A. K., & Nagarsenkar, M. (2020). Recent trends in excipient development for oral drug delivery. Drug Development and Industrial Pharmacy, 46(11), 1692–1703.

[3] US Food and Drug Administration. (2021). Inactive Ingredients Database. https://www.fda.gov/drugs/pharmaceutical-quality-resources/inactive-ingredients-database

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.